Fortrea(FTRE.US)

Company Encyclopedia
View More
name
Fortrea
FTRE.US
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical services that provides development and consulting services to clinical pharmacology and clinical development spectrum. The company also offers delivery models that include full service, functional service provider, and hybrid service structures. In addition, it delivers phase I – IV clinical trial management, clinical pharmacology, and consulting services.
808.26 B
FTRE.USMarket value -Rank by Market Cap -/-

Financial Score

12/01/2026 Update
D
Life Sciences Tools and ServicesIndustry
Industry Ranking45/61
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-98.13%E
    • Profit Margin-36.77%E
    • Gross Margin17.50%D
  • Growth ScoreD
    • Revenue YoY1.88%C
    • Net Profit YoY-215.38%E
    • Total Assets YoY-25.15%E
    • Net Assets YoY-61.63%E
  • Cash ScoreD
    • Cash Flow Margin-271.94%D
    • OCF YoY1.88%C
  • Operating ScoreB
    • Turnover0.86B
  • Debt ScoreE
    • Gearing Ratio78.82%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Fortrea (NASDAQ:FTRE) Upgraded to "Strong-Buy" at Truist Financial

    Truist Financial upgraded Fortrea (NASDAQ:FTRE) from a "hold" to a "strong-buy" rating. Other analysts have varied opinions, with Mizuho raising the target price to $13.00 and Barclays setting it at $15.00. Fortrea's stock opened at $17.44, with a market cap of $1.61 billion. The company reported a quarterly EPS of $0.12, missing estimates, but had revenue of $701.30 million. Fortrea, a CDMO, focuses on integrated solutions for pharmaceutical companies, having spun off from Thermo Fisher Scientific in October 2023.

    Market Beat·
    US
    FTRE
    -0.29%
    Market Beat·
    US
    FTRE
    -0.29%

    Fortrea Announces Updated Presentation Time at Upcoming J.P. Morgan Healthcare Conference | FTRE Stock News

    Fortrea (Nasdaq: FTRE) has announced an updated presentation time of 11:15 am PST on January 13, 2026, at the J.P. Morgan Annual Healthcare Conference in San Francisco. CEO Anshul Thakral, CFO Jill McConnell, and SVP of Investor Relations, Tracy Krumme, will participate. The event will be accessible via a live webcast on Fortrea’s Investor Relations website. Fortrea is a global contract research organization providing clinical development solutions to the life sciences industry, with a focus on accelerating therapies to patients.

    StockTitan·
    US
    FTRE
    -0.29%
    StockTitan·
    US
    FTRE
    -0.29%

    Expert Outlook: Fortrea Holdings Through The Eyes Of 6 Analysts

    Fortrea Holdings (NASDAQ:FTRE) has received mixed ratings from 6 analysts over the past three months, with an average 12-month price target of $15.5, reflecting a 50.05% increase from the previous target. Analysts have raised their ratings, with notable increases from firms like Evercore ISI and Citigroup. Despite revenue growth of 3.91%, Fortrea's financial metrics, including net margin (-2.27%) and return on equity (-2.72%), are below industry averages, indicating potential challenges. The company, formed from Labcorp's spin-off, operates as a global contract research organization with 19,000 employees across 90 countries.

    benzinga_article·
    US
    FTRE
    -0.29%
    benzinga_article·
    US
    FTRE
    -0.29%

    Fortrea Executives to Present at J.P. Morgan Healthcare Conference

    Fortrea Holdings Inc. will present at the J.P. Morgan Annual Healthcare Conference on January 13, 2025, in San Francisco. CEO Anshul Thakral, CFO Jill McConnell, and SVP of Investor Relations Tracy Krumme will participate in a presentation and Q&A session at 5:15 pm PST. A live webcast and replay will be available on Fortrea’s Investor Relations website.

    Reuters·
    US
    FTRE
    -0.29%
    Reuters·
    US
    FTRE
    -0.29%

    Fortrea (NASDAQ:FTRE) Upgraded to Hold at Barclays

    Barclays upgraded Fortrea (NASDAQ:FTRE) from "strong sell" to "hold." Other analysts have varied ratings, with Citigroup upgrading to "buy" and Weiss Ratings maintaining a "sell." The stock opened at $16.06, with a market cap of $1.48 billion. Fortrea reported $0.12 EPS, missing estimates. Institutional investors have adjusted their positions in the company. Fortrea provides biopharmaceutical and medical device development services globally.

    Market Beat·
    US
    FTRE
    -0.29%
    Market Beat·
    US
    FTRE
    -0.29%
    © 2026 Longbridge｜Disclaimer